Efgartigimod
- Generic Name
- Efgartigimod
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Phase 3
Completed
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Other: Placebo
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- argenx
- Target Recruit Count
- 131
- Registration Number
- NCT04188379
- Locations
- 🇺🇸
Investigator Site 0010040, Columbus, Ohio, United States
🇬🇪Investigator Site 9950008, Tbilisi, Georgia
🇵🇱Investigator Site 0480008, Katowice, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath